Expression of hMSH2 correlates with in vitro chemosensitivity to CDDP cytotoxicity in oral and oropharyngeal carcinoma

Cancer Letters

Volumn 132, Issue 1-2, 1998, Pages 37-44

  Fujieda, Shigeharu ^a   Tanaka, Nobuyuki ^a   Sunaga, Hiroshi ^a   Noda, Ichiro ^a   Sugimoto, Chizuru ^a   Tsuzuki, Hideaki ^a   Saito, Hitoshi ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

CDDP; Chemosensitivity; Head and neck cancer; hMSH2; Mismatch repair protein

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; MITOMYCIN C; PEPLEOMYCIN; PROTEIN; PROTEIN MSH2; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CHEMOSENSITIVITY; CHROMOSOME 2P; CONTROLLED STUDY; DRUG CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CISPLATIN; DNA-BINDING PROTEINS; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MITOMYCIN; MOUTH NEOPLASMS; MUTS HOMOLOG 2 PROTEIN; OROPHARYNGEAL NEOPLASMS; PEPLOMYCIN; PROTO-ONCOGENE PROTEINS; TUMOR CELLS, CULTURED;

EID: 0032561163     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00157-8     Document Type: Article

References (36)

1. Fishel R., Lescoe M.K., Rao M.R.S., Copeland N.G., Jenkins N.A., Garber J., Kane M., Kolodner R. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell. 75:1993;1027-1038.
2. F.S. Leach, N.C. Nicolaides, N. Papadopoulos, B. Liu, J. Jen, R. Parsons, P. Peltomäki, P. Sistonen, L.A. Aaltonen, M. Nyström-Lahti, X.Y. Guan, J. Zhang, P.S. Meltzer, J.W. Yu, F.T. Kao, D.J. Chen, K.M. Cerosaletti, R.E.K. Fournier, S. Todd, T. Lewis, R.J. Leach, S.L. Naylor, J. Weissenbach, J.P. Mecklin, H. Järvinen, G.M. Petersen, S.R. Hamilton, J. Green, J. Jass, P. Watson, H.T. Lynch, J.M. Trent, A. Chapelle, K.W. Kinzler, B. Vogelstein, Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer, Cell 75 (1993) 1215-1225.
3. Aaltonen L.A., Peltomäki P., Leach F.S., Sistone P., Pylkkänen L., Mecklin J.P., Järvinen H., Powell S.M., Jen J., Hamilton S.R., Petersen G.M., Kinzler K.W., Vogelstein B., Chapelle A. Clues to the pathogenesis of familial colorectal cancer. Science. 260:1993;812-816.
4. Thibodeau S.N., Bren G., Schaid D. Microsatellite instability in cancer of the proximal colon. Science. 260:1993;816-819.
5. Koi M., Umar A., Chauhan D.P., Cherian S.P., Carethers J.M., Kunkel T.A., Boland C.R. Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N′-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMSH1 mutation. Cancer Res. 54:1994;4308-4312.
6. Aquilina G., Hess P., Branch P., MacGeoch C., Casciano I., Karran P., Bignami M. A mismatch recognition defect in colon carcinoma confers DNA microsatellite instability and a mutator phenotype. Proc. Natl. Acad. Sci. USA. 91:1994;8905-8909.
7. Bronner C.E., Baker S.M., Morrison P.T., Warren G., Smith L.G., Lescoe M.K., Kane M., Earabino C., Lipford J., Lindblom A., Tannergård P., Bollag R.J., Godwin A.R., Ward D.C., Nordenskjøld M., Fishel R., Kolodner R., Liskay R.M. Mutation in the DNA mismatch repair gene homologue hMSH1 is associated with hereditary non-polyposis colon cancer. Nature. 368:1994;258-261.
8. Umar A., Boyer J.C., Thomas D.C., Nguyen D.C., Risinger J.I., Boyd J., Ionov Y., Perucho M., Kunkel T.A. Defective mismatch repair in extracts of colorectal and endometrial cancer cell lines exhibiting microsatellite instability. J. Biol. Chem. 269:1994;14367-14370.
9. Boyer J.C., Umar A., Risinger J.I., Lipford J.R., Kane M., Yin S., Barrett J.C., Kolodner R.D., Kunkel T.A. Microsatellite instability, mismatch repair deficiency, and genetic defects in human cancer cell lines. Cancer Res. 55:1995;6063-6070.
10. Liu B., Parsons R., Papadopoulos N., Nicolaides N.C., Lynch H.T., Watson P., Jass R.J., Dunlop M., Wyllie A., Peltomäki P., Chapelle A., Hamilton S.R., Vogelstein B., Kinzler K.W. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat. Med. 2:1996;169-174.
11. Katabuchi H., Rees B., Lambers A.R., Ronnett B.M., Blazes M.S., Leach F.S., Cho K.R., Hedrick L. Mutations in DNA mismatch repair genes are not responsible for microsatellite instability in most sporadic endometrial carcinomas. Cancer Res. 55:1995;5556-5560.
12. Risinger J.I., Umar A., Boyer J.C., Evans A.C., Berchuck A., Kunkel T.A., Barrett J.C. Microsatellite instability in gynecological sarcomas and in hMSH2 mutant uterine sarcoma cell lines defective in mismatch repair activity. Cancer Res. 55:1995;5664-5669.
13. Bubb V.J., Curtis L.J., Cunningham C., Dunlop M.G., Carothers A.D., Morris R.G., White S., Bird C.C., Wyllie A.H. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene. 12:1996;2641-2649.
14. Thibodeau S.N., French A.J., Roche P.C., Cunningham J.M., Tester D.J., Lindor N.M., Moslein G., Baker S.M., Liskay R.M., Burgart L.J., Honchel R., Halling K.C. Altered expression of hMSH2 and hMSH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 56:1996;4836-4840.
15. Drummond J.T., Li G.M., Longley M.J., Modrich P. Isolation of an hMSH2-p160 heterodimer that restores DNA mismatch repair to tumor cells. Science. 268:1995;1909-1912.
16. Palombo F., Gallinari P., Iaccarino I., Lettieri T., Hughes M., D'Arrigo A., Truong O., Hsuan J.J., Jiricny J. GTBP, a 160-kilodalton protein essential for mismatch-binding activity in human cells. Science. 268:1995;1912-1914.
17. 4-methylthymine, or the cisplatin-d(GpG) adduct. Proc. Natl. Acad. Sci. USA. 93:1996;6443-6447.
18. Abei S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., Christen R.D., Boland C.R., Koi M., Fishel R., Howell S.B. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res. 56:1996;3087-3090.
19. Fink D., Nebel S., Abei S., Zheng H., Cenni B., Nehmé A., Christen R.D., Howell S.B. The role of DNA mismatch repair in platinum drug resistance. Cancer Res. 56:1996;4881-4886.
20. Fink D., Zheng H., Nebel S., Norris P.S., Abei S., Lin T.P., Nehmé A., Christen R.D., Haas M., MacLeod C.L., Howell S.B. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 57:1997;1841-1845.
21. Tsuzuki H., Fujieda S., Sunaga H., Ichiro N., Saito H. Expression of granulocyte colony-stimulating factor receptor correlates with prognosis in oral and mesopharyngeal carcinoma. Cancer Res. 58:1998;794-800.
22. Leach F.S., Polyak K., Burrell M., Johnson K.A., Hill D., Dunlop M.G., Wyllie A.H., Peltomäki P., Chapelle A., Hamilton S.R., Kinzler K.W., Vogelstein B. Expression of the human mismatch repair gene hMSH2 in normal and neoplastic tissues. Cancer Res. 56:1996;235-240.
23. Fujieda S., Noda I., Saito H., Hoshino T., Yagita M. Swainsonine augments the cytotoxicity of human lymphokine-activated killer cells against autologous thyroid cancer cells. Arch. Otolaryngol. Head Neck Surg. 120:1994;389-394.
24. Fujieda S., Noda I., Saito H., Hoshino T., Yagita M. Heat shock enhances the susceptibility of tumor cells to lysis by lymphokine-activated killer cells. Arch. Otolaryngol. Head Neck Surg. 121:1995;1009-1014.
25. Garewal H.S., Ahmann F.R., Schifman R.B., Celniker A. ATP assay: ability to distinguish cytostatic from cytocidal anticancer drug effects. J. Natl. Cancer Inst. 77:1986;1039-1045.
26. Thibodeau S.N., French A.J., Roche P.C., Cunningham J.M., Tester D.J., Lindor N.M., Moslein G., Baker S.M., Liskay R.M., Burgart L.J., Honchel R., Halling K.C. Altered expression of hMSH2 and hMSH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res. 564:1996;4836-4840.
27. Wei Q., Bondy M.L., Mao B.L., Guan Y., Cheng L., Cunningham J., Fan Y., Bruner J.M., Yung W.K.A., Levin V.A., Kyritsis A.P. Reduced expression of mismatch repair genes measured by multiplex reverse transcription-polymerase chain reaction in human gliomas. Cancer Res. 57:1997;1673-1677.
28. Reitmair A.H., Schmits R., Ewel A., Bapat B., Redston M., Mitri A., Waterhouse P., Mittrücker H.W., Wakeham A., Liu B., Thomason A., Griesser H., Gallinger G., Ballhausen W.G., Fishel R., Mak T.W. MSH2 deficient mice are viable and susceptible to lymphoid tumours. Nat. Genet. 11:1995;64-70.
29. Lowsky R., DeCoteau J.F., Reitmair A.H., Ichinohasama R., Dong W.F., Xu Y., Mak T.W., Kadin M.E., Minden M.D. Defects of the mismatch repair gene MSH2 are implicated in the development of murine and human lymphoblastic lymphomas and are associated with the aberrant expression of Rhombotin-2 (Lmo-2) and Tal-1 (SCL). Blood. 89:1997;2276-2282.
30. Reitmair A.H., Cai J.C., Bjerknes M., Redston M., Cheng H., Pind M.T.L., Hay K., Mitri A., Bapat B.V., Mak T.W., Gallinger S. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Cancer Res. 56:1996;2922-2926.
31. Uzawa K., Yoshida H., Suzuki H., Tanzawa H., Shimazaki J., Seino S., Sato K. Abnormalities of the adenomatous polyposis coli gene in human oral squamous-cell carcinoma. Int. J. Cancer. 58:1994;814-817.
32. Paulson T.G., Wright F.A., Parker B.A., Russack V., Wahl G.M. Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. Cancer Res. 56:1996;4021-4026.
33. Saito H., Otsubo T., Fujieda S., Tanigawa N. Chemosensitivity of head and neck cancer with the rapid thymidine incorporation assay and its clinical application. Eur. Arch. Otorhinolaryngol. 249:1992;400-403.
34. Andreotti P.E., Cree L.A., Kurbacher C.M., Hartmann D.M., Linder D., Harel G., Gleiberman I., Caruso P.A., Ricks S.H., Untch M., Sartori C., Bruckner H.W. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 55:1995;5276-5282.
35. Brown E., Markman M. Tumor chemosensitivity and chemoresistance assays. Cancer. 77:1996;1020-1025.
36. Cortazar P., Gazdar A.F., Woods E., Russell E., Steinberg S.M., Williams J., Ihde D.C., Johnson B.E. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing. Clin. Cancer Res. 3:1997;741-747.